2024
Patient Characteristics and Practice Variation Associated With New Community Prescription of Benzodiazepine and z‐Drug Hypnotics After Critical Illness: A Retrospective Cohort Study Using the UK Clinical Practice Research Datalink
Mansi E, Rentsch C, Bourne R, Guthrie B, Lone N. Patient Characteristics and Practice Variation Associated With New Community Prescription of Benzodiazepine and z‐Drug Hypnotics After Critical Illness: A Retrospective Cohort Study Using the UK Clinical Practice Research Datalink. Pharmacoepidemiology And Drug Safety 2024, 33: e70056. PMID: 39603606, PMCID: PMC11602247, DOI: 10.1002/pds.70056.Peer-Reviewed Original ResearchConceptsCommunity prescriptionsZ-drugsIllness survivorsRetrospective cohort studyClinical Practice Research Datalink dataPractice variationUK Clinical Practice Research DatalinkClinical Practice Research DatalinkWorsening mental health conditionsCohort studyMultilevel multivariable logistic regressionSurvivors of critical illnessZ-drug prescribingCritical care survivorsPrimary care practicesCritical illnessMental health conditionsZ-drug prescriptionsCritical illness survivorsMultivariate logistic regressionPrescription opioid useCare practicesRisk of adverse eventsHealth conditionsHistory of insomniaImpact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY
Wiedemann M, Speed V, Cunningham C, Higgins R, Curtis H, Andrews C, Fisher L, Hopcroft L, Rentsch C, Mahalingasivam V, Tomlinson L, Morton C, Samuel M, Green A, Wood C, Brown A, Massey J, Walters C, Smith R, Inglesby P, Evans D, Maude S, Dillingham I, Walker A, Morley J, Mehrkar A, Bacon S, Bates C, Cockburn J, Parry J, Hester F, McManus R, Goldacre B, MacKenna B. Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY. Open Heart 2024, 11: e002732. PMID: 39214534, DOI: 10.1136/openhrt-2024-002732.Peer-Reviewed Original ResearchConceptsBlood pressure screeningPressure screeningPercentage of patientsHypertension prevalenceHypertension managementPopulation-based cohort studyRecord of hypertensionCardiovascular disease managementClinical subgroupsQOF indicatorsScreening ratesPrimary careGeneral practiceHome statusNHS patientsOlder peopleBlood pressure measurementsCare schemesCohort studyDisease managementImpact of COVID-19COVID-19Framework indicatorsNational qualityNHSIncident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records
Doran W, Tunnicliffe L, Muzambi R, Rentsch C, Bhaskaran K, Smeeth L, Brayne C, Williams D, Chaturvedi N, Eastwood S, Dunachie S, Mathur R, Warren-Gash C. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Research & Care 2024, 12: e003548. PMID: 38272537, PMCID: PMC10823924, DOI: 10.1136/bmjdrc-2023-003548.Peer-Reviewed Original ResearchConceptsRisk of dementiaMild cognitive impairmentOral glucose-lowering therapyDementia riskObservational cohort studyAs-treated analysisGlucose-lowering therapyRisk of incident all-cause dementiaUK adultsCompare risk of dementiaIncident all-cause dementiaType 2 diabetesClinical Practice Research DatalinkActive comparator new user designCohort studyAll-cause dementiaPrimary healthcare recordsIncident dementia riskAssociated with lower riskPotential exposure misclassificationCox proportional hazards regressionMetformin useRisk of confoundingProportional hazards regressionIncident dementia
2023
Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosis
2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypesAssociation Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAntiviral AgentsCohort StudiesHepacivirusHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisAre infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records
Muzambi R, Bhaskaran K, Rentsch C, Smeeth L, Brayne C, Garfield V, Williams D, Chaturvedi N, Warren-Gash C. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records. Translational Psychiatry 2022, 12: 385. PMID: 36109502, PMCID: PMC9478085, DOI: 10.1038/s41398-022-02145-z.Peer-Reviewed Original ResearchConceptsCognitive declineWhite matter hyperintensity volumeSecondary care recordsAssociation of infectionHistory of infectionPotential structural correlatesEvidence of associationCommon infectionsDementia riskHyperintensity volumeInfection diagnosisCare recordsCognitive impairmentLinear mixed effects modelsCognitive functionVolunteer cohortInfectionMixed effects modelsStructural correlatesUK BiobankLinear regression modelsAssociationEffects modelRegression modelsVisual memoryPotentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old
Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old. Pharmacoepidemiology And Drug Safety 2022, 31: 1056-1074. PMID: 35780391, PMCID: PMC9464694, DOI: 10.1002/pds.5506.Peer-Reviewed Original ResearchConceptsLevel of polypharmacyRace/ethnicityPIM prevalencePrevalence of PIMsInappropriate medication useElectronic health recordsCommon PIMsPharmacy fillsPROMPT criteriaInappropriate medicationsOlder patientsMedication usePsychotropic medicationsRefill recordsPolypharmacyPatientsVeterans AffairsMedicationsPrevalenceHealth recordsFiscal year 2016AgeMeaningful differencesSexTarget ageValidation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations
Chen F, Darst BF, Madduri RK, Rodriguez AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, Cho K, Jalloh M, Gueye SM, Niang L, Ogunbiyi OJ, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Adjei AA, Diop H, Lachance J, Rebbeck TR, Ambs S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife 2022, 11: e78304. PMID: 35801699, PMCID: PMC9322982, DOI: 10.7554/elife.78304.Peer-Reviewed Original ResearchConceptsProstate cancer riskPolygenic risk scoresProstate cancerCancer riskOdds ratioMillion Veteran ProgramRisk scoreRisk stratification toolAge-specific absolute risksAfrican ancestry menCancer odds ratiosVeterans Health AdministrationCase-control studyNonaggressive prostate cancerProstate Cancer FoundationAge-specific riskAssociation of PRSPRS categoriesRisk-stratified screeningVeteran ProgramNational Cancer InstituteEuropean ancestry menStratification toolAbsolute riskEffect modificationAssociations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National InstitutesOverall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
Bhaskaran K, Rentsch CT, Hickman G, Hulme WJ, Schultze A, Curtis HJ, Wing K, Warren-Gash C, Tomlinson L, Bates CJ, Mathur R, MacKenna B, Mahalingasivam V, Wong A, Walker AJ, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Parry J, Hester F, Harper S, Evans SJ, Bacon S, Smeeth L, Goldacre B. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLOS Medicine 2022, 19: e1003871. PMID: 35077449, PMCID: PMC8789178, DOI: 10.1371/journal.pmed.1003871.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCOVID-19 hospitalisationGeneral population controlsCOVID-19 groupCOVID-19 survivorsHospital admissionHigh riskInfluenza hospitalisationsCause mortalityCohort studyInfluenza patientsPrimary careGeneral populationInitial infectionAcute coronavirus disease 2019Lower respiratory tract infectionsSevere COVID-19 outcomesLong-term adverse outcomesCOVID-19 hospital admissionsSpecific causesPopulation controlsCause-specific hospitalisationRespiratory tract infectionsCause-specific outcomesPotential risk factorsGeographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States
Ferguson JM, Justice AC, Osborne TF, Magid HSA, Purnell AL, Rentsch CT. Geographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States. Scientific Reports 2022, 12: 273. PMID: 34997001, PMCID: PMC8741774, DOI: 10.1038/s41598-021-03967-5.Peer-Reviewed Original Research
2021
OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
Collaborative T, Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton C, Bacon S, Hickman G, Inglesby P, Bates C, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson E, Hulme W, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wong AY, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Goldacre B. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart 2021, 8: e001784. PMID: 34785588, PMCID: PMC8595296, DOI: 10.1136/openhrt-2021-001784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsBlood CoagulationBlood Coagulation TestsCOVID-19Drug MonitoringDrug PrescriptionsDrug SubstitutionDrug UtilizationEnglandFactor Xa InhibitorsFemaleHumansMaleMiddle AgedPatient SafetyPractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareRetrospective StudiesRisk AssessmentRisk FactorsState MedicineWarfarinConceptsWarfarin patientsNational Health ServiceCOVID-19 pandemicNational guidanceCare home residencyINR test resultsRenal function testsFrequent blood testingSafety alertsRoutine clinical dataAtrial fibrillation diagnosisElevated INRMedication changesOral anticoagulantsAnticoagulant therapyCohort studyAppropriate patientsINR testsFunction testsBlood testingPrimary careClinical dataDOACPatientsWarfarinAssociation between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Wong A, Tomlinson L, Brown J, Elson W, Walker A, Schultze A, Morton C, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch C, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis H, Mehrkar A, Cockburn J, McDonald H, Mathur R, Wing K, Forbes H, Eggo R, Evans S, Smeeth L, Goldacre B, Douglas I. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal Of Hematology & Oncology 2021, 14: 172. PMID: 34666811, PMCID: PMC8525065, DOI: 10.1186/s13045-021-01185-0.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPopulation-based cohort studyCOVID-19-related outcomesSevere COVID-19Oral anticoagulantsCohort studyHazard ratioLower riskNegative control outcome analysisSevere COVID-19 diseaseNon-valvular atrial fibrillationPrimary care dataCOVID-19 outcomesCOVID-19COVID-19 diseaseNegative control outcomesDOAC usersOpenSAFELY platformWarfarin usersHospital admissionAtrial fibrillationClinical evidenceCox regressionResultsA totalOutcome analysisProtease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionRisks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform
Williamson EJ, McDonald HI, Bhaskaran K, Walker AJ, Bacon S, Davy S, Schultze A, Tomlinson L, Bates C, Ramsay M, Curtis HJ, Forbes H, Wing K, Minassian C, Tazare J, Morton CE, Nightingale E, Mehrkar A, Evans D, Inglesby P, MacKenna B, Cockburn J, Rentsch CT, Mathur R, Wong AYS, Eggo RM, Hulme W, Croker R, Parry J, Hester F, Harper S, Douglas IJ, Evans SJW, Smeeth L, Goldacre B, Kuper H. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. The BMJ 2021, 374: n1592. PMID: 34261639, PMCID: PMC8278652, DOI: 10.1136/bmj.n1592.Peer-Reviewed Original ResearchConceptsCovid-19 related hospital admissionRelated hospital admissionsNon-COVID deathsHospital admissionOpenSAFELY platformDown syndromeCohort studyHazard ratioCerebral palsyDisability registersGeneral practiceCOVID-19COVID-19 hospital admissionsMain exposure groupsCOVID-19 vaccinationHospital admission dataPatient-level dataLow event ratesNon-COVID causesCOVID-19 testingTargeted preventive measuresWave 2Wave 1Electronic health recordsProfound learning disabilitiesPharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Gerlovin H, Posner DC, Ho YL, Rentsch CT, Tate JP, King JT, Kurgansky KE, Danciu I, Costa L, Linares FA, Goethert ID, Jacobson DA, Freiberg MS, Begoli E, Muralidhar S, Ramoni RB, Tourassi G, Gaziano JM, Justice AC, Gagnon DR, Cho K. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. American Journal Of Epidemiology 2021, 190: 2405-2419. PMID: 34165150, PMCID: PMC8384407, DOI: 10.1093/aje/kwab183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsAzithromycinCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisMachine LearningMaleMiddle AgedPharmacoepidemiologyRetrospective StudiesSARS-CoV-2Treatment OutcomeUnited StatesVeteransConceptsUS veteransCOVID-19Veterans Affairs Health Care SystemRecent randomized clinical trialsAdministration of hydroxychloroquineEffectiveness of hydroxychloroquineRisk of intubationEffect of hydroxychloroquineElectronic health record dataRandomized clinical trialsTreatment of patientsUS veteran populationCOVID-19 outcomesCoronavirus disease 2019Health record dataRigorous study designsHealth care systemSurvival benefitTreat analysisEarly therapyHospitalized populationClinical trialsObservational studyDisease 2019HydroxychloroquineRelationship Between Glycemia and Cognitive Function, Structural Brain Outcomes, and Dementia: A Mendelian Randomization Study in the UK Biobank.
Garfield V, Farmaki AE, Fatemifar G, Eastwood SV, Mathur R, Rentsch CT, Denaxas S, Bhaskaran K, Smeeth L, Chaturvedi N. Relationship Between Glycemia and Cognitive Function, Structural Brain Outcomes, and Dementia: A Mendelian Randomization Study in the UK Biobank. Diabetes 2021, 70: 2313-2321. PMID: 33632741, DOI: 10.2337/db20-0895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiological Specimen BanksBlood GlucoseBrainCognitionDementiaDiabetes Mellitus, Type 2FemaleGenome-Wide Association StudyGlycated HemoglobinHumansMaleMemoryMendelian Randomization AnalysisMiddle AgedOrgan SizePolymorphism, Single NucleotidePrognosisReaction TimeRisk FactorsUnited KingdomWhite MatterConceptsWhite matter hyperintensity volumeType 2 diabetesHippocampal volumeAlzheimer's dementiaRisk of ADCognitive functionMendelian randomizationBrain structuresStructural brain outcomesGenetic instrumentsMR sensitivity analysesUK BiobankVisual memoryMendelian randomization studyIncident dementiaBrain outcomesDiabetes riskHyperintensity volumeMeasures of cognitionPeripheral glycemiaBidirectional Mendelian randomizationDiabetesRandomization studyCausal associationGlycemiaAssociation between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England
Forbes H, Morton CE, Bacon S, McDonald HI, Minassian C, Brown JP, Rentsch CT, Mathur R, Schultze A, DeVito NJ, MacKenna B, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Drysdale H, Wong AYS, Cockburn J, McManus R, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Evans SJW, Bhaskaran K, Eggo RM, Goldacre B, Tomlinson LA. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. The BMJ 2021, 372: n628. PMID: 33737413, PMCID: PMC7970340, DOI: 10.1136/bmj.n628.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionIntensive care admissionHospital admissionCare admissionCohort studyCOVID-19Covid-19 related hospital admissionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Wave 2Primary care dataRelated hospital admissionsSyndrome coronavirus 2Adults 65 yearsCohort of adultsCOVID-19 outcomesCoronavirus disease 2019COVID-19 mortalityRisk of infectionWave 1UK pandemicHazard ratioIntensive careAbsolute riskUK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, Mansfield KE, Rentsch CT, Douglas IJ, Mathur R, Wong AYS, Quint JK, Andrews N, Bernal JL, Scott JA, Ramsay M, Smeeth L, McDonald HI. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health 2021, 21: 484. PMID: 33706738, PMCID: PMC7948667, DOI: 10.1186/s12889-021-10427-2.Peer-Reviewed Original ResearchConceptsSevere COVID-19Health conditionsElectronic health recordsHigh riskRisk populationsCOVID-19Clinical Practice Research Datalink GOLDSevere COVID-19 diseaseSecondary care recordsChronic kidney diseaseHealth recordsChronic liver diseasePoint prevalence studyBinomial exact confidence intervalsOlder age groupsPublic health interventionsWorking-aged individualsCOVID-19 diseaseWorking-aged adultsUK prevalenceCurrent asthmaLiver diseaseCancer survivorsPoint prevalenceKidney disease